CN110498833A - 一种具有ace抑制作用的三肽及其应用 - Google Patents
一种具有ace抑制作用的三肽及其应用 Download PDFInfo
- Publication number
- CN110498833A CN110498833A CN201910813070.1A CN201910813070A CN110498833A CN 110498833 A CN110498833 A CN 110498833A CN 201910813070 A CN201910813070 A CN 201910813070A CN 110498833 A CN110498833 A CN 110498833A
- Authority
- CN
- China
- Prior art keywords
- tripeptides
- ace
- product
- blood pressure
- inhibitory activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract description 23
- 230000000694 effects Effects 0.000 claims abstract description 18
- 230000036772 blood pressure Effects 0.000 claims abstract description 12
- 230000000968 intestinal effect Effects 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 7
- RZRDCZDUYHBGDT-BVSLBCMMSA-N Trp-Met-Tyr Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O RZRDCZDUYHBGDT-BVSLBCMMSA-N 0.000 claims abstract description 6
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 230000036541 health Effects 0.000 claims abstract description 6
- 230000009467 reduction Effects 0.000 claims abstract description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 229940088598 enzyme Drugs 0.000 claims description 4
- 108010019160 Pancreatin Proteins 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 230000009849 deactivation Effects 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 230000010355 oscillation Effects 0.000 claims description 3
- 229940055695 pancreatin Drugs 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 102000057297 Pepsin A Human genes 0.000 claims description 2
- 108090000284 Pepsin A Proteins 0.000 claims description 2
- 229940111202 pepsin Drugs 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000029087 digestion Effects 0.000 abstract description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 8
- 238000000338 in vitro Methods 0.000 abstract description 5
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 33
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 33
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 33
- 238000001514 detection method Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 5
- 101000984728 Chiropsoides quadrigatus Angiotensin-converting enzyme inhibitory peptide Proteins 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 229910052796 boron Inorganic materials 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229910021538 borax Inorganic materials 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 235000010339 sodium tetraborate Nutrition 0.000 description 3
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 238000011017 operating method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 208000010470 Ageusia Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102000048186 Endothelin-converting enzyme 1 Human genes 0.000 description 1
- 108030001679 Endothelin-converting enzyme 1 Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000019666 ageusia Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Polymers & Plastics (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种具有ACE抑制作用的三肽WMY，该三肽的氨基酸序列为Trp‑Met‑Tyr。本发明公开的三肽ACE抑制活性明显，且能够抵抗胃肠道消化作用，在体外模拟胃肠道消化后，消化产物的ACE抑制活性增强，具有潜在的降血压功效，可应用于降血压的食品、保健品及药品中。
Description
技术领域
本发明属于生物活性肽领域，具体涉及具有ACE抑制作用的三肽及其应用。
背景技术
高血压是全球性公共健康问题，长期高血压是引发冠状动脉疾病、中风、心力衰竭、心房颤动、外周血管疾病、视力丧失等疾病的主要危险因素，更是全球死亡率最大的单一因素。目前，治疗高血压主要通过药物作用实现，但长期服用抗高血压药物所引起的副作用不容忽视，包括干咳，高钾血症，疲劳，头晕，头痛，味觉丧失和血管性水肿等。
血压调节机制非常复杂，血管紧张素转化酶(ACE)、肾素、内皮素I和内皮素转化酶、钙通道、阿片受体等都是血压调节系统的重要组成部分。其中ACE参与了两个BP调节相关的系统，即激肽释放酶-激肽系统(KKS)和肾素-血管紧张素系统(RAS)，在血压调节过程中起着极其重要的作用。ACE可通过切割没有活性的血管紧张素ⅠC末端的二肽，生成具有活性的血管紧张素Ⅱ，血管紧张素Ⅱ是一种有效的血管收缩剂，同时ACE还可水解舒缓激肽，使其失活，最终导致血压升高。ACE抑制肽，是一类通过抑制ACE活性从而达到降血压效果的小分子生物活性多肽总称，可通过抑制ACE的活性，达到无毒副作用的降血压效果。
此外，目前的功能性肽产品主要为口服产品，均需要通过人体内的胃肠道才能被吸收，而存在于胃肠道的酶系会对多肽的进一步降解导致多肽的生物活性改变。因此，获得在经过胃肠消化吸收后仍具有明显ACE抑制活性的功能性肽显得尤为重要。
发明内容
本发明的目的在于提供一种经过胃肠消化吸收后仍具有明显ACE抑制作用的三肽及其应用。
本发明的目的通过下述技术方案实现：
一种三肽，其氨基酸序列为Trp-Met-Tyr(WMY)，分子量为499.2009Da，具有明显的ACE抑制活性，且经胃肠消化后其ACE抑制活性进一步增强，具有明显的降血压功效。
Trp表示英文名为Tryptophan，中文名为色氨酸的氨基酸的相应残基。
Met表示英文名为DL-Methionine，中文名为甲硫氨酸的氨基酸的相应残基。
Tyr表示英文名为Tyrosine，中文名为酪氨酸的氨基酸的相应残基。
所述三肽的胃肠道消化产物，由以下步骤制得：
配制Trp-Met-Tyr溶液，将其pH值调至2.0，加入胃蛋白酶后置于恒温振荡摇床，在37℃下反应2h，然后将其pH值调至5.3后再调至7.5，加入胰酶，37℃下反应4h，沸水浴灭酶10min，冷冻干燥得到胃肠道消化产物。
本发明的三肽WMY可通过化学合成法等方式合成。
本发明的ACE抑制肽可用于制备降血压药物、保健品和食品。
本发明的三肽WMY能与ACE结合，抑制ACE活性，从而降低血压。
本发明的三肽WMY经胃肠道消化后，ACE抑制活性增强，表现出潜在的降血压功效。
本发明相对于现有技术具有如下的优点及效果：
(1)本发明提供的ACE抑制肽具有明显的ACE抑制活性，且经胃肠消化后其ACE抑制活性进一步增强，具有明显的降血压功效，可用于药品、保健品和食品中。
(2)本发明提供的强ACE抑制肽为三肽产品，其分子量小，易于被人体直接吸收利用。
附图说明
图1是WMY和LVLL及其消化产物对ACE活性的影响。
具体实施方式
下面结合实施例及附图对本发明作进一步详细的描述，但本发明的实施方式不限于此。
本发明实施例中所涉及的试验指标其实验方法如下：
(1)ACE抑制活性的测定
将30μL底物(HHL，5mM)与20μL一定浓度的样品或硼酸钠缓冲液(pH值8.3，0.1M硼酸，0.3M氯化钠)混合，在37℃下温浴5min，加入30μL ACE溶液(0.1U/L)启动反应，在37℃下反应30min，加入10μL HCl(0.1M)终止反应，并通过高效液相色谱法测定其在228nm处的峰面积。反应体系总体积为90μL，且底物、样品、ACE溶液均由硼酸钠缓冲液配置。ACE抑制活性计算公式如下：
ACE抑制率(ACEI)＝(A空白-A样品)/A空白×100％
式中，A样品指样品组产物HA峰面积；A空白指硼酸钠缓冲液组产物HA峰面积。
色谱条件为ZORBAX Eclipse XDB-C18分析色谱柱(5μm 4.5*250mm)；检测波长：228nm；流速：0.5ml/min；柱温：30℃；进样量：10μL，自动进样；流动相：A为乙腈，B为0.5％TFA；洗脱条件：0-11min A 20％、B 80％，12-15min，A 20-35％、B 80-65％，16-17min，A35-20％、B 65-80％，18-25min，A 20％、B80％。
(2)体外模拟胃肠道消化
配制10mg/ml的Trp-Met-Tyr溶液，用HCl(1M)将其pH值调至2.0，加入2％(w/w)胃蛋白酶后置于恒温振荡摇床，在37℃下反应2h，然后用NaHCO3(0.9M)将其pH值调至5.3后再用NaOH调至7.5，加入2％(w/w)胰酶，37℃下反应4h，沸水浴灭酶10min，冷冻干燥得到体外模拟胃肠道消化产物。
实施例1
三肽WMY浓度为400μmol/L时，其ACE抑制活性为52.77±2.32％。
检测方法：将通过化学合成法获得的此三肽，进行活性检测，检测方法同上述方法(1)。
实施例2
三肽WMY体外胃肠道模拟消化产物能够有效的抑制ACE活性，且其ACE抑制活性较三肽WMY有所提升。
检测方法：将通过化学合成法获得的此三肽，进行体外模拟胃肠道消化，操作方法同上述方法(2)，此时浓度为400μmol/L。
对比例1
四肽LVLL浓度为400μmol/L时，其ACE抑制活性为41.87±1.43％。
检测方法：将通过化学合成法获得的此四肽，进行活性检测，检测方法同上述方法(1)。
对比例2
四肽LVLL体外胃肠道模拟消化产物对ACE活性无显著影响。
检测方法：将通过化学合成法获得的此四肽，进行体外模拟胃肠道消化，操作方法同上述方法(2)，此时浓度为400μmol/L。
由图1可知，本文发明三肽WMY具有明显的ACE抑制活性，且经过体外模拟胃肠道消化后，ACE抑制活性高达64.43±2.43，相较于三肽WMY提升了22.10±1.57％，而四肽LVLL经体外胃肠道模拟消化后，ACE抑制活性降低了81.73±3.68％，仅有7.65±0.05％的抑制活性。
说明本发明三肽不仅具有ACE抑制活性，还具备消化活性增强特性，具有潜在降血压效果，可用于药品、保健品或食品等行业中。
上述实施例为本发明较佳的实施方式，但本发明的实施方式并不受上述实施例的限制，其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化，均应为等效的置换方式，都包含在本发明的保护范围之内。
Claims (6)
1.一种三肽，其特征在于氨基酸序列为Trp-Met-Tyr。
2.根据权利要求1所述的三肽，其特征在于：分子量为499.2009Da。
3.权利要求1或2所述三肽的胃肠道消化产物。
4.根据权利要求3所述的三肽的胃肠道消化产物，其特征在于由以下步骤制得：
配制Trp-Met-Tyr溶液，将其pH值调至2.0，加入胃蛋白酶后置于恒温振荡摇床，在37℃下反应2h，然后将其pH值调至5.3后再调至7.5，加入胰酶，37℃下反应4h，沸水浴灭酶10min，冷冻干燥得到胃肠道消化产物。
5.权利要求1或2所述的三肽在制备具有降血压功效的药品、食品和保健品中的应用。
6.权利要求3或4所述的三肽的胃肠道消化产物在制备具有降血压功效的药品、食品和保健品中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910813070.1A CN110498833B (zh) | 2019-08-30 | 2019-08-30 | 一种具有ace抑制作用的三肽及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910813070.1A CN110498833B (zh) | 2019-08-30 | 2019-08-30 | 一种具有ace抑制作用的三肽及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110498833A true CN110498833A (zh) | 2019-11-26 |
| CN110498833B CN110498833B (zh) | 2021-01-15 |
Family
ID=68590710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910813070.1A Active CN110498833B (zh) | 2019-08-30 | 2019-08-30 | 一种具有ace抑制作用的三肽及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110498833B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220072348A (ko) * | 2020-11-25 | 2022-06-02 | (주)케어젠 | 미세먼지에 의한 세포 손상 방지 활성을 갖는 펩타이드 및 이의 용도 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1780639A (zh) * | 2003-03-18 | 2006-05-31 | 三得利株式会社 | 血管紧张素转化酶抑制肽 |
| CN101429231A (zh) * | 2007-11-06 | 2009-05-13 | 光明乳业股份有限公司 | 一种抗高血压活性三肽及其制备方法和应用 |
| JP2010222300A (ja) * | 2009-03-24 | 2010-10-07 | Nagoya Univ | 機能性ペプチドを表すルールの抽出法、機能性ペプチドの設計法及び調製法、ポリペプチド又はポリペプチド含有組成物の評価法、並びに機能性ペプチド |
| CN101906135A (zh) * | 2010-07-27 | 2010-12-08 | 鲁军 | 一种新型螺旋藻源降血压肽及其制备方法 |
| CN103254278A (zh) * | 2005-06-08 | 2013-08-21 | 康斯乔最高科学研究公司 | 奶酪蛋白的酶水解产物中鉴定的生物活性肽及其生产方法 |
-
2019
- 2019-08-30 CN CN201910813070.1A patent/CN110498833B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1780639A (zh) * | 2003-03-18 | 2006-05-31 | 三得利株式会社 | 血管紧张素转化酶抑制肽 |
| CN103254278A (zh) * | 2005-06-08 | 2013-08-21 | 康斯乔最高科学研究公司 | 奶酪蛋白的酶水解产物中鉴定的生物活性肽及其生产方法 |
| CN101429231A (zh) * | 2007-11-06 | 2009-05-13 | 光明乳业股份有限公司 | 一种抗高血压活性三肽及其制备方法和应用 |
| JP2010222300A (ja) * | 2009-03-24 | 2010-10-07 | Nagoya Univ | 機能性ペプチドを表すルールの抽出法、機能性ペプチドの設計法及び調製法、ポリペプチド又はポリペプチド含有組成物の評価法、並びに機能性ペプチド |
| CN101906135A (zh) * | 2010-07-27 | 2010-12-08 | 鲁军 | 一种新型螺旋藻源降血压肽及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| DUANGJAI A.等: "Characterisation of an extract and fractions of Azadirachta indica flower on cholesterol lowering property and intestinal motility" Duangjai A.等，《Natural", 《NATURAL PRODUCT RESEARCH》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220072348A (ko) * | 2020-11-25 | 2022-06-02 | (주)케어젠 | 미세먼지에 의한 세포 손상 방지 활성을 갖는 펩타이드 및 이의 용도 |
| KR102474470B1 (ko) | 2020-11-25 | 2022-12-07 | (주)케어젠 | 미세먼지에 의한 세포 손상 방지 활성을 갖는 펩타이드 및 이의 용도 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110498833B (zh) | 2021-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5612131B2 (ja) | 糖尿病の治療または予防剤 | |
| Jimsheena et al. | Angiotensin I-converting enzyme (ACE) inhibitory peptides derived from arachin by simulated gastric digestion | |
| DK2473518T3 (en) | Stabilized melanocortin ligands | |
| Wester et al. | Stabilization of Angiotensin-(1–7) by key substitution with a cyclic non-natural amino acid | |
| CN110498833A (zh) | 一种具有ace抑制作用的三肽及其应用 | |
| CN108929370A (zh) | 三种具有ace抑制活性的鸡蛋源活性肽 | |
| CN106317178A (zh) | 一种具有降尿酸活性的多肽及其应用 | |
| CN117801070B (zh) | 一种美白祛斑消水肿青稞酒糟肽及其制备方法和应用 | |
| CN108840909B (zh) | 一种紫菜降压肽和紫菜降压肽提取物及应用 | |
| CN106554387A (zh) | 具有ace和dpp-iv双重抑制活性的九肽及其应用 | |
| CN108129561A (zh) | 一种ace抑制肽 | |
| JP3472801B2 (ja) | アンジオテンシンｉ変換酵素阻害剤およびその製造法 | |
| JP2010024165A (ja) | オキアミタンパク質由来アンジオテンシン変換酵素阻害剤 | |
| JP3193085B2 (ja) | アンギオテンシン変換酵素阻害剤含有組成物の製造方法 | |
| JPH04282398A (ja) | アンジオテンシン変換酵素阻害ペプチド | |
| CN113072621A (zh) | 一种牦牛骨降血压肽及其制备方法与应用 | |
| CA2423876C (en) | Novel selective bradykinin (bk) b1 peptidic receptor antagonists and uses thereof | |
| CN110540577A (zh) | 一种具有降血压作用的鸭源多肽及其应用 | |
| JP2003284551A (ja) | アンジオテンシンｉ変換酵素阻害剤 | |
| CN108948143A (zh) | 具有ace抑制活性的三肽及其应用 | |
| CN113087767B (zh) | 具有降血压功能的三肽rfy及其用途 | |
| CN113444145B (zh) | 一种聚球藻血管紧张素转化酶抑制肽及其制备方法与应用 | |
| CN112694429B (zh) | 一类多肽及其在制备ace抑制剂或降血压产品上的应用 | |
| JP2010018552A (ja) | ソヤサポニンｉを含有するレニン阻害剤 | |
| KR100318553B1 (ko) | 안지오텐신-1-전환효소억제활성을갖는신규한생리활성펩타이드 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: Nansha District Avenue South Ring of 511458 cities in Guangdong province Guangzhou City, No. 25 Hua Da Guangzhou production and Research Institute Applicant after: SOUTH CHINA University OF TECHNOLOGY Applicant after: GUANGZHOU INSTITUTE OF MODERN INDUSTRIAL TECHNOLOGY Address before: 510640 Tianhe District, Guangdong, No. five road, No. 381, Applicant before: SOUTH CHINA University OF TECHNOLOGY Applicant before: GUANGZHOU INSTITUTE OF MODERN INDUSTRIAL TECHNOLOGY |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |